Quotient Limited (NASDAQ: QTNT) and NanoString Technologies (NASDAQ:NSTG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitabiliy, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Quotient Limited and NanoString Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quotient Limited 0 0 2 0 3.00
NanoString Technologies 0 1 2 0 2.67

Quotient Limited currently has a consensus price target of $19.00, suggesting a potential upside of 193.21%. NanoString Technologies has a consensus price target of $20.00, suggesting a potential upside of 24.38%. Given Quotient Limited’s stronger consensus rating and higher possible upside, analysts plainly believe Quotient Limited is more favorable than NanoString Technologies.

Risk and Volatility

Quotient Limited has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.

Valuation & Earnings

This table compares Quotient Limited and NanoString Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Quotient Limited $22.23 million 4.19 -$64.60 million ($3.01) -2.15
NanoString Technologies $89.86 million 3.88 -$42.26 million ($2.48) -6.48

NanoString Technologies has higher revenue and earnings than Quotient Limited. NanoString Technologies is trading at a lower price-to-earnings ratio than Quotient Limited, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quotient Limited and NanoString Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Quotient Limited -382.71% -1,303.22% -77.72%
NanoString Technologies -57.13% -6,777.29% -46.14%

Insider and Institutional Ownership

38.6% of Quotient Limited shares are owned by institutional investors. Comparatively, 87.1% of NanoString Technologies shares are owned by institutional investors. 40.5% of Quotient Limited shares are owned by company insiders. Comparatively, 24.4% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

NanoString Technologies Company Profile

NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.

Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.